CARM1 Antibody - #BF0658

(3)   (7)  
Product: CARM1 Antibody
Catalog: BF0658
Description: Mouse monoclonal antibody to CARM1
Application: WB IHC IF/ICC ELISA FACS
Reactivity: Human, Rat, Monkey
Mol.Wt.: 65kDa; 66kD(Calculated).
Uniprot: Q86X55
RRID: AB_2833878

View similar products>>

   Size Price Inventory
 50ul $250 In stock
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Mouse
Application:
ELISA 1:10000, WB 1:500-1:2000, IHC 1:200-1:1000, IF/ICC 1:200-1:1000, FCM 1:200-1:400
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Rat,Monkey
Clonality:
Monoclonal [AFB1854]
Specificity:
CARM1 antibody detects endogenous levels of total CARM1.
RRID:
AB_2833878
Cite Format: Affinity Biosciences Cat# BF0658, RRID:AB_2833878.
Conjugate:
Unconjugated.
Purification:
Affinity-chromatography.
Storage:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

carm1; CARM1_HUMAN; Coactivator associated arginine methyltransferase 1; Coactivator-associated arginine methyltransferase 1; Histone arginine methyltransferase CARM 1; Histone arginine methyltransferase CARM1; Histone-arginine methyltransferase CARM1; PRMT 4; PRMT4; Protein arginine methyltransferase; Protein arginine N methyltransferase 4; Protein arginine N-methyltransferase 4;

Immunogens

Immunogen:

Purified recombinant fragment of human CARM1 expressed in E. Coli.

Uniprot:

Q86X55(CARM1_HUMAN) >>Visit HPA database.

Gene(ID):
CARM1(10498)
Expression:
Q86X55 CARM1_HUMAN:

Overexpressed in prostate adenocarcinomas and high-grade prostatic intraepithelial neoplasia.

Description:
Protein arginine N-methyltransferases, such as CARM1, catalyze the transfer of a methyl group from S-adenosyl-L-methionine to the side chain nitrogens of arginine residues within proteins to form methylated arginine derivatives and S-adenosyl-L-homocysteine. Protein arginine methylation has been implicated in signal transduction, metabolism of nascent pre-RNA, and transcriptional activation (Frankel et al. 2002 (PubMed 11724789). Tissue specificity: Overexpressed in prostate adenocarcinomas and high-grade prostatic intraepithelial neoplasia.
Sequence:
MAAAAAAVGPGAGGAGSAVPGGAGPCATVSVFPGARLLTIGDANGEIQRHAEQQALRLEVRAGPDSAGIALYSHEDVCVFKCSVSRETECSRVGKQSFIITLGCNSVLIQFATPNDFCSFYNILKTCRGHTLERSVFSERTEESSAVQYFQFYGYLSQQQNMMQDYVRTGTYQRAILQNHTDFKDKIVLDVGCGSGILSFFAAQAGARKIYAVEASTMAQHAEVLVKSNNLTDRIVVIPGKVEEVSLPEQVDIIISEPMGYMLFNERMLESYLHAKKYLKPSGNMFPTIGDVHLAPFTDEQLYMEQFTKANFWYQPSFHGVDLSALRGAAVDEYFRQPVVDTFDIRILMAKSVKYTVNFLEAKEGDLHRIEIPFKFHMLHSGLVHGLAFWFDVAFIGSIMTVWLSTAPTEPLTHWYQVRCLFQSPLFAKAGDTLSGTCLLIANKRQSYDISIVAQVDQTGSKSSNLLDLKNPFFRYTGTTPSPPPGSHYTSPSENMWNTGSTYNLSSGMAVAGMPTAYDLSSVIASGSSVGHNNLIPLANTGIVNHTHSRMGSIMSTGIVQGSSGAQGSGGGSTSAHYAVNSQFTMGGPAISMASPMSIPTNTMHYGS

PTMs - Q86X55 As Substrate

Site PTM Type Enzyme
A2 Acetylation
R49 Methylation
T171 Phosphorylation
Y172 Phosphorylation
S216 Phosphorylation
K227 Ubiquitination
S228 Phosphorylation
R234 Methylation
K276 Acetylation
K276 Methylation
K363 Ubiquitination
K444 Ubiquitination
S447 Phosphorylation
K462 Ubiquitination
K470 Ubiquitination

Research Backgrounds

Function:

Methylates (mono- and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in several proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability. Recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families, methylates histone H3 at 'Arg-17' (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activate transcription via chromatin remodeling. During nuclear hormone receptor activation and TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. During monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B. Acts as coactivator for PPARG, promotes adipocyte differentiation and the accumulation of brown fat tissue. Plays a role in the regulation of pre-mRNA alternative splicing by methylation of splicing factors. Also seems to be involved in p53/TP53 transcriptional activation. Methylates EP300/P300, both at 'Arg-2142', which may loosen its interaction with NCOA2/GRIP1, and at 'Arg-580' and 'Arg-604' in the KIX domain, which impairs its interaction with CREB and inhibits CREB-dependent transcriptional activation. Also methylates arginine residues in RNA-binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA-stabilizing properties and the half-life of their target mRNAs.

PTMs:

Auto-methylated on Arg-550. Methylation enhances transcription coactivator activity. Methylation is required for its role in the regulation of pre-mRNA alternative splicing (By similarity).

Phosphorylation at Ser-216 interferes with S-adenosyl-L-methionine binding and strongly reduces methyltransferase activity (By similarity). Phosphorylation at Ser-216 is strongly increased during mitosis, and decreases rapidly to a very low, basal level after entry into the G1 phase of the cell cycle. Phosphorylation at Ser-216 may promote location in the cytosol.

Subcellular Location:

Nucleus. Cytoplasm.
Note: Mainly nuclear during the G1, S and G2 phases of the cell cycle. Cytoplasmic during mitosis, after breakup of the nuclear membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Overexpressed in prostate adenocarcinomas and high-grade prostatic intraepithelial neoplasia.

Subunit Structure:

Homodimer (Probable). Interacts with the C-terminus of NCOA2/GRIP1, NCO3/ACTR and NCOA1/SRC1. Part of a complex consisting of CARM1, EP300/P300 and NCOA2/GRIP1. Interacts with FLII, TP53, myogenic factor MEF2, EP300/P300, TRIM24, CREBBP and CTNNB1. Identified in a complex containing CARM1, TRIM24 and NCOA2/GRIP1. Interacts with NCOA3/SRC3. Interacts with SNRPC (By similarity). Interacts with NR1H4. Interacts with RELA.

(Microbial infection) Interacts with HTLV-1 protein Tax.

Family&Domains:

Belongs to the class I-like SAM-binding methyltransferase superfamily. Protein arginine N-methyltransferase family.

Research Fields

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

References

1). Bexarotene improves motor function after spinal cord injury in mice. Neural Regeneration Research, 2023 (PubMed: 37449638) [IF=6.1]

Application: WB    Species: Mouse    Sample: spinal cord

Figure 10 Bexarotene activates TFE3 through the AMPK-mTOR and AMPK-SPK2- CARM1 signaling pathways in SCI. (A) Western blot assay of the cytoplasmic expression levels of AMPK, p-AMPK, mTOR, and p-mTOR. (B) Quantification of AMPK, p-AMPK, mTOR, and p-mTOR from A, normalized to GADPH. (C) Western blot assay of the nuclear expression levels of AMPK, p-AMPK, FOXO3a, p-FOXO3a, SKP2, and CARM1. (D) Quantification of AMPK, p-AMPK, FOXO3a, p-FOXO3a, SKP2, and CARM1 from C, normalized to H3. (E, F) Immunoprecipitation images showing nuclear CARM1–TFE3 binding. Data are expressed as the mean ± SEM (n = 6 per group). **P < 0.01, vs. SCI group; ##P < 0.01, vs. SCI + Bex group. One-way analysis of variance with least significance difference post hoc test. (p-)AMPK: (phospho-) adenosine 5′-monophosphate-activated protein kinase; (p-)FOXO3a: (phospho-)forkhead box O3; (p-)mTOR: (phospho-)mammalian target of rapamycin; Bex: bexarotene; CARM1: coactivator-associated arginine methyltransferase 1; CC: compound C; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; H3: histone protein H3; SCI: spinal cord injury; SKP2: S-phase kinase-associated protein 2; TFE3: transcription factor E3.
2). 贝沙罗汀改善脊髓损伤后运动功能的机制. 中国神经再生研究(英文版), 2023 (PubMed: 37449638) [IF=6.1]

Application: WB    Species: Mouse    Sample:

Figure 10 Bexarotene activates TFE3 through the AMPK-mTOR and AMPK-SPK2- CARM1 signaling pathways in SCI. (A) Western blot assay of the cytoplasmic expression levels of AMPK, p-AMPK, mTOR, and p-mTOR. (B) Quantification of AMPK, p-AMPK, mTOR, and p-mTOR from A, normalized to GADPH. (C) Western blot assay of the nuclear expression levels of AMPK, p-AMPK, FOXO3a, p-FOXO3a, SKP2, and CARM1. (D) Quantification of AMPK, p-AMPK, FOXO3a, p-FOXO3a, SKP2, and CARM1 from C, normalized to H3. (E, F) Immunoprecipitation images showing nuclear CARM1–TFE3 binding. Data are expressed as the mean ± SEM (n = 6 per group). **P < 0.01, vs. SCI group; ##P < 0.01, vs. SCI + Bex group. One-way analysis of variance with least significance difference post hoc test. (p-)AMPK: (phospho-) adenosine 5′-monophosphate-activated protein kinase; (p-)FOXO3a: (phospho-)forkhead box O3; (p-)mTOR: (phospho-)mammalian target of rapamycin; Bex: bexarotene; CARM1: coactivator-associated arginine methyltransferase 1; CC: compound C; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; H3: histone protein H3; SCI: spinal cord injury; SKP2: S-phase kinase-associated protein 2; TFE3: transcription factor E3.
3). RPF2 mediates the CARM1‑MYCN axis to promote chemotherapy resistance in colorectal cancer cells. Oncology reports, 2024 (PubMed: 37997821) [IF=4.2]

Application: WB    Species: Mouse    Sample: colorectal cancer cells

Figure 3. Molecular mechanism exploration and animal experiments in vivo. (A) Intracellular expression of ABCB1, MYCN and CARM1 was detected by western blotting. Expression of ABCB1 was significantly increased in the RPF2 group (P

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.